CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Barinthus Biotherapeutics PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Barinthus Biotherapeutics PLC - ADR
The Schrdinger Building
Heatley Road, The Oxford Science Park
Phone: +44 1865818808p:+44 1865818808 DIDCOT, OX11 0DF  United Kingdom Ticker: BRNSBRNS
Business Summary
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board RobinWright 58 10/1/2018 8/1/2018
Chief Executive Officer, Director William J.Enright 62 8/1/2019 8/1/2019
Chief Financial Officer, Company Secretary GemmaBrown 34 9/15/2022 9/15/2022
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Avidea Technologies Inc. 1812 Ashland Ave. Baltimore MD United States

Business Names
Business Name
Avidea Technologies Inc.
Barinthus Biotherapeutics (UK) Limited
Barinthus Biotherapeutics Italia S.R.L.
9 additional Business Names available in full report.

General Information
Number of Employees: 130 (As of 12/31/2023)
Outstanding Shares: 79,770,974 (As of 10/30/2024)
Shareholders: 70
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024